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Tinnitus is unusual for such a common symptom in that there are few treatment options
and those that are available are aimed at reducing the impact rather than specifically
addressing the tinnitus percept. In particular, there is no drug recommended specifically
for the management of tinnitus. Whilst some of the currently available interventions
are effective at improving quality of life and reducing tinnitus-associated psychological
distress, most show little if any effect on the primary symptom of subjective tinnitus
loudness. Studies of the delivery of tinnitus services have demonstrated considerable
end-user dissatisfaction and a marked disconnect between the aims of healthcare
providers and those of tinnitus patients: patients want their tinnitus loudness reduced
and would prefer a pharmacological solution over other modalities. Several studies
have shown that tinnitus confers a significant financial burden on healthcare systems
and an even greater economic impact on society as a whole. Market research
has demonstrated a strong commercial opportunity for an effective pharmacological
treatment for tinnitus, but the amount of tinnitus research and financial investment
is small compared to other chronic health conditions. There is no single reason for
this situation, but rather a series of impediments: tinnitus prevalence is unclear with
published figures varying from 5.1 to 42.7%; there is a lack of a clear tinnitus definition
and there are multiple subtypes of tinnitus, potentially requiring different treatments;
there is a dearth of biomarkers and objective measures for tinnitus; treatment research
is associated with a very large placebo effect; the pathophysiology of tinnitus is unclear;
animal models are available but research in animals frequently fails to correlate with
human studies; there is no clear definition of what constitutes meaningful change
or “cure”; the pharmaceutical industry cannot see a clear pathway to distribute their
products as many tinnitus clinicians are non-prescribing audiologists. To try and clarify
this situation, highlight important areas for research and prevent wasteful duplication
of effort, the British Tinnitus Association (BTA) has developed a Map of Tinnitus. This
is a repository of evidence-based tinnitus knowledge, designed to be free to access,
intuitive, easy to use, adaptable and expandable.
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INTRODUCTION
Tinnitus is a common symptom, yet there are few effective
treatment options and those that are available are aimed
at ameliorating the impact rather than offering hope of a
cure. Tinnitus support agencies often reflect their members’
exasperation at the lack of potentially curative treatment options.
For example, the online support organization, TinnitusHub1, has
the following text as part of its Statement of Research: “One thing
that both our users and we share in common is a strong desire
for a cure. The patient population in general feels frustration
and impatience; why isn’t there a cure, why don’t we understand
more, why are we not hearing of breakthroughs and feeling
hope, where is the funding?” The reasons behind this apparent
impasse are complex.
PATIENT AND PROVIDER
PERSPECTIVES ON TINNITUS
TREATMENT OPTIONS
How Effective Are Current Tinnitus
Management Strategies?
Tinnitus management options that have been subjected to
randomized controlled trial (RCT) investigation include
pharmacological interventions, sound-based interventions,
psychological interventions, magnetic stimulation, electrical
stimulation, manual physical therapy, relaxation therapy,
complementary and alternative medicine (CAM) therapies,
education and information, self-help interventions and complex
interventions (defined as a combination or two or more of the
preceding modalities). Most trials have investigated methods of
reducing the day-to-day impact of tinnitus rather than looking
for long-term or potentially curative treatments that target the
underlying causes of the disorder.
Psychology-based interventions, particularly those based on
cognitive behavior therapy (CBT) are often cited as the most
efficacious of current tinnitus treatments. Yet this modality
is aimed at reducing tinnitus-associated distress rather than
reducing the tinnitus per se. Systematic review and meta-analysis
of trials of CBT for tinnitus have been conducted and have
shown that CBT is effective at improving quality of life and
reducing tinnitus-associated depression (Martinez-Devesa et al.,
2010). However, when the primary outcome of subjective tinnitus
loudness is considered, the same systematic review found no
evidence of a difference between CBT and either no treatment
or another intervention.
Are Tinnitus Patients Satisfied With
Current Tinnitus Services?
For such a common complaint, remarkably little research
has been conducted into the aspirations and expectations of
patients with tinnitus. Various studies have collected data
on perceptions of tinnitus services from general practitioners
1https://www.tinnitushub.com/
(GPs), ENT physicians and audiologists (El-Shunnar et al.,
2011; Gander et al., 2011; Hoare et al., 2012) but patients’
voices have largely been ignored. A recent study from the
United States has redressed this by circulating questionnaires
to a group of audiologists and a group of patients (Husain
et al., 2018). Data from 230 adults with tinnitus and 68
audiologists were analyzed and revealed a large disconnect
between the aspirations of the two communities. When
asked to define treatment success, audiologists identifying
decreased awareness (77%) and stress/anxiety relief (63%)
whereas patients sought reduction of tinnitus loudness (63%),
and elimination of tinnitus (57%). The area of greatest
agreement was that both groups felt that supplying more
information regarding tinnitus is helpful. When patients were
asked “how effectively is your healthcare provider able to treat
or manage your tinnitus?” 82.6% of respondents replied, “not
at all effectively” or “not very effectively.” Only 3.5% thought
that their tinnitus had been managed “very effectively” or
“extremely effectively.”
A study of tinnitus management in the United Kingdom
(McFerran et al., 2018) obtained responses from 937 individuals
and demonstrated that the United Kingdom healthcare system
performs well at investigating people with tinnitus and excluding
serious underlying pathology but markedly less so when it
comes to treating the problem: 67.7% of patients who were
investigated appropriately were not offered any therapeutic
assistance. Many of these expressed their dissatisfaction by
returning to their primary care physician only to be rereferred
back to secondary care, creating unsatisfactory and expensive
revolving door healthcare.
A study of quality of life in patients with tinnitus
in Sweden (Zarenoe and Ledin, 2014) included questions
regarding the participants’ satisfaction with the healthcare
services that they had received for their tinnitus. Out of
the total of 376 respondents who commented on treatment
given within the ENT clinic, 147 (39.1%) felt they had
received “good” or “very good” treatment, 54 (14.4%) felt
the treatment was “OK” but 175 (46.5%) felt their treatment
was “not good” or they had received no treatment. An
optional free text box was included in the questionnaire asking
participants about their perception of the tinnitus service they
received. Of the 159 answers to this question, 25 respondents
commented that they had received an audiometric examination
but no treatment.
Dedicated tinnitus services fare better but even here there is
dissatisfaction: a survey of patients attending a specialist tinnitus
clinic (the Tinnitus Clinic of the Welsh Hearing Institute) were
surveyed regarding the perceived benefits and shortcomings of
the clinic (Sanchez and Stephens, 2000). The biggest criticism
of the clinic was that 17.1% described the interventions and
treatments as ineffective.
A research priority setting exercise was undertaken for
tinnitus (Hall et al., 2013) in which patients, families, and
clinicians partnered to identify the top ten tinnitus research
priorities. Of these ten priorities, seven pertained directly
to the improvement of existing treatments/therapies, or the
identification of novel interventions.
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What Treatment(s) Do Tinnitus Patients
Want?
One key question is whether patients with tinnitus would be
willing to accept novel treatment modalities for their tinnitus,
such as drug treatments or surgery. A study undertaken by Tyler
(2012) investigated patient preferences and their willingness to
accept and pay for various forms of treatment. The potential
treatment modalities comprised external devices, a pill, a cochlear
implant, devices surgically implanted onto the surface of the
brain or devices surgically implanted into the substance of the
brain. This study demonstrated that the most commonly desired
treatment modality for tinnitus was an effective drug: 52% would
be very likely to try medication if it offered tinnitus loudness
and annoyance reduction of a half, rising to 62% if it offered the
chance of complete elimination of the percept.
Is There Financial Benefit to Obtaining a
Cure for Tinnitus?
One reason that new treatment options, including
pharmaceuticals, have not emerged could be that there would be
little financial benefit to companies producing these treatments
or little benefit to the healthcare systems and society as a whole.
However, this is clearly not the case: the management of tinnitus
carries a significant financial burden to healthcare systems and
society. Economic modeling of costs in the United Kingdom
suggested that the average cost of tinnitus treatment per patient
per year in 2016 was GB£717, equating to a total healthcare bill of
GB£750 million per annum or approximately 0.6% of the annual
healthcare budget (Stockdale et al., 2017). Using previously
described methodology (Cima et al., 2012) societal costs were
estimated at GB£2.7 billion per annum.
An economic study undertaken in the United States in
2015 gave broadly similar figures to the United Kingdom
study, estimating healthcare costs at US$660 per patient per
year (Goldstein et al., 2015). A Dutch study (Maes et al.,
2013) suggested even higher figures with an estimated mean
annual tinnitus-related cost per patient of €1544, though this
study made the assumption that all patients with tinnitus were
actively seeking help for their condition and may therefore be
an overestimate.
Further evidence for the financial and healthcare resource
cost of tinnitus is demonstrated by the fact that tinnitus is now
the number one service-related disability seen amongst military
veterans in the United States. A statement from the foremost
American non-profit organization committed to curing tinnitus,
The American Tinnitus Association (ATA)2, reported that there
were 971,990 Veteran’s Administration claims for tinnitus in
2012, resulting in payment of $1.2 billion on tinnitus-related
compensation to veterans.
The commercial rewards for a company that could bring
an effective pharmacological treatment for tinnitus to market
are likely to be considerable. An estimate produced by the
2https://www.ata.org/news/press-release/treating-and-curing-tinnitus-part-our-
national-commitment-veterans
United Kingdom hearing charity, RNID (now Action on Hearing
Loss3) suggested that a novel tinnitus drug could have a product
value of $689 million in its first year of launch (Vio and
Holme, 2005). This study also estimated that at that time, there
were 13 million people in Western Europe and United States
actively seeking help for their tinnitus and that 4 million off-label
prescriptions for tinnitus were written each year.
Is the Amount of Ongoing Tinnitus
Research Proportionate to the Size of
the Problem?
One way of trying to assess the level of research interest in
tinnitus is to benchmark it against a range of other neurological
or neuropsychiatric disorders. A search of the United States
National Library of Medicine trials registration website,
clinicaltrials.gov4, was conducted using the following parameters:
1. Condition.
2. Interventional studies (clinical trials).
3. Targeted search. Intervention/treatment “drug”.
The conditions entered into the search were chronic pain,
depression, anxiety, hearing loss or deafness and tinnitus: results
are presented in Table 1.
This is clearly not a systematically accurate reflection of the
research interest in these conditions: not all clinical trials are
registered on the clinicaltrials.gov website and the website’s search
tools detect broad categories but lack precision. Furthermore,
many drug trials investigate factors such as drug side effects
and safety rather than drug efficacy. Nevertheless, the figures
can be used to demonstrate the relative research interest and
show that tinnitus falls behind other comparable conditions:
depression has over 27 times more registered trials in general
and more than 44 times more registered trials relating to
drug interventions than tinnitus. The situation is very similar
when scientific publications on these conditions are considered.
A search of the United States National Library of Medicine’s
PubMed5 database was performed for the following conditions:
depression, anxiety, deafness OR hearing loss, tinnitus. The
3https://www.actiononhearingloss.org.uk
4https://clinicaltrials.gov/
5https://www.ncbi.nlm.nih.gov/pubmed
TABLE 1 | A list of trials registered on the clinicaltrials.gov website, showing both
total number of trials and those trials investigating drug interventions for the
relevant condition (such conducted on).
Condition Total registered trials Interventional trials
using drugs
Chronic pain 2235 855
Depression 5509 2440
Anxiety 2826 921
Hearing loss/deafness 494 94
Tinnitus 200 55
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number of publications per year between 1940 and 2017 is
depicted in Figure 1.
The search was then repeated for these conditions AND
[(pharmacological treatment) OR (drug treatment)]. The results
of this search are displayed in graphical form in Figure 2.
The results demonstrate the large difference in research output
between the various conditions, with depression having 30.5
times more scientific publications in 2017 compared to tinnitus.
When attention is turned to drug therapies, the comparison is
even more stark: there were 49.0 times more drug treatment
related publications for depression in 2017 compared to the
output for tinnitus.
OBSTACLES TO A CURE
Supply Versus Demand: A Therapeutic
Paradox
The preceding observations clearly demonstrate that there are
economic and patient driven pressures to find a cure or at least
an effective management paradigm for tinnitus that are not being
met by current research resources. In the following sections, we
review some of the obstacles that impede the identification and
development of new treatment options for patients with tinnitus.
Tinnitus Research Funding
Cederroth et al. (2013) compared national funding available
for hearing and tinnitus research against national funding for
diabetes research: in United States, between 2009 and 2011,
average annual funding for diabetes by the National Institutes
of Health (NIH)6was $913 million compared to $214 million
for hearing disorders, of which only $5 million was allocated to
tinnitus projects. In the same period in the European Union,
funding by the Framework Programme 7 (FP7)7 system resulted
in annual funding of approximately $60 million for diabetes,
compared to $3.3 million for hearing disorder projects. There
was no tinnitus research funded by FP7. The editorial recognized
that tinnitus research is also funded by charities, other non-
governmental organizations and philanthropists but concluded
that tinnitus research funding is sparse in comparison with other
disorders with similar healthcare burdens.
A more recent study from Blustein (2019) confirmed that
NIH funding allocated to hearing loss still remains low, in spite
of recent evidence by the Global Burden of Disease (GBD)
study which showed that hearing loss is now the 4th leading
cause of years lived with disability (YLDs) (Wilson et al., 2017).
Information on tinnitus is not yet available in the GBD database –
inclusion would be useful as a tool for demonstrating need to both
research funders and healthcare organizations.
In contrast, funding in Europe has improved lately with the
European Commission awarding financial support in the form
of Marie Skłodowska-Curie Actions (MSCA)8 grants financed
6https://www.nih.gov/
7https://ec.europa.eu/research/fp7
8https://ec.europa.eu/programmes/horizon2020/en/h2020-section/marie-
sklodowska-curie-actions
FIGURE 1 | Publications listed on the United States National Library of Medicine PubMed database for the conditions tinnitus, deafness, anxiety or depression in the
period from 1940 to 2017.
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FIGURE 2 | Publications listed on the United States National Library of Medicine PubMed database for the search [(pharmacological treatment) OR (drug treatment)]
AND condition (conditions: tinnitus, deafness, anxiety or depression) in the time period from 1940 to 2017.
through the Horizon 2020 funding programme9. Projects funded
through this system include the TIN-ACT: Tinnitus Assessment,
Causes and Treatments project10 and the European School
for Interdisciplinary Tinnitus Research (ESIT) project11 (Schlee
et al., 2018) which received approximately €3.9 million and
€3.8 million respectively. While such funding improvements are
very welcome, it is noteworthy that tinnitus projects continue
to receive a small proportion of the total funding budget:
MCSA grants have been allocated to 405 projects related to
diabetes, 75 related to deafness or hearing loss but only nine
related to tinnitus.
Tinnitus Research Structure
Tinnitus research is by nature multidisciplinary and can
encompass multiple academic disciplines including auditory
neuroscience, psychology, audiology, physiology, pharmacology,
computer modeling, bioengineering, and clinical medicine –
including both otological surgery and neurosurgery. Globally
there are very few research centers where cross-specialty
expertise is available to cover and integrate this huge breadth
of research topics. Ultimately it may be necessary to review
and revise the structure of academic careers in tinnitus.
Projects such as ESIT which are training tomorrow’s tinnitus
researchers go some way to addressing this deficiency, but
more is needed.
Unclear Tinnitus Prevalence
One of the first issues regarding engagement of the
pharmaceutical industry in a search for a tinnitus drug is
9https://ec.europa.eu/programmes/horizon2020
10https://tinact.eu/
11https://esit.tinnitusresearch.net/
a lack of agreement on the size of the patient population.
A systematic review of tinnitus prevalence studies in adults
identified 39 different studies (McCormack et al., 2016). Overall
prevalence varied over eightfold from 5.1 to 42.7%. The authors
attributed a significant part of this variation to the way in which
tinnitus had been defined in the individual studies, but even
when the review was restricted to the 12 studies that had used the
same definition of tinnitus, prevalence estimates varied almost
threefold from 11.9 to 30.3%. When study quality was assessed,
almost half the included studies had a high risk of bias and
the authors concluded that the data were too heterogeneous to
warrant meta-analysis. Furthermore, these prevalence studies do
not always explore the impact of the reported tinnitus and hence
do not estimate the proportion that would seek pharmaceutical
treatment if it became available.
Some studies have attempted to address the size of the
disease burden: figures from the United Kingdom, suggest that
around 6 million people (10% of the population) have some
form of tinnitus, with about 600,000 (1%) experiencing it to
an extent that it affects their quality of life (National Institute
for Health and Care Excellence, NICE12). Another analysis in
the United Kingdom by Davis and El Rafaie (2000) from the
MRC longitudinal study of hearing of 48,313 people found that
10.1% of adults had experienced episodes of tinnitus lasting
more than 5 min, and in 5% the tinnitus was moderately or
severely annoying. However, only 0.5% of the study population
were affected severely enough for their tinnitus to have a serious
impact on their ability to lead a normal life. Clearly the number
of people with the symptom and its effect on them are only
part of the story: other factors such as the safety and side effect
profile of any tinnitus drug and its cost would have to be taken
12https://cks.nice.org.uk/tinnitus#!topicSummary
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into consideration. However, even limiting take-up to the 0.5–
1% of the population with life-altering tinnitus results in a
substantial market.
Ambiguous Tinnitus Definitions and
Subtyping
Multiple definitions of tinnitus have been published from
“ringing or buzzing in the ears” (Oxford Dictionary13) to “the
conscious experience of a sound that originates in the head
of its owner” (McFadden, 1982) or “the conscious perception
of an auditory sensation in the absence of a corresponding
external stimulus” (Baguley et al., 2013). None of these definitions
are entirely fit for purpose. Ringing in the ears is clearly too
simplistic – awareness of tinnitus does not have to be within
the ears and many sounds other than ringing are reported. The
other definitions (McFadden, 1982; Baguley et al., 2013) are more
accurate descriptors of tinnitus, but would include the auditory
hallucinations seen in some forms of psychiatric illness. Also,
some examples of pulsatile tinnitus are generated mechanically,
for example, by muscular or vascular activity. Similarly, some
examples of low frequency noise complaint are responses to
genuine low-frequency noise in the person’s environment though
others are probably phantom perceptions which would fall
underneath the tinnitus umbrella (Baguley et al., 2016).
The various subdivisions of negative reaction to both real and
phantom sounds are depicted graphically in Figure 3.
Most tinnitus trials are conducted in subjects with persistent
spontaneous tinnitus also known as subjective idiopathic
tinnitus. This is the group of tinnitus sufferers whose tinnitus
is non-pulsatile and not related to a small number of
specific medical conditions or syndromes including Meniere’s
disease, otosclerosis and vestibular schwannoma. However, this
group is extremely unlikely to be a homogeneous population
either in terms of their tinnitus pathogenesis or tinnitus
experience. Describing tinnitus as idiopathic in particular seems
inappropriate: the majority of subjects presenting with tinnitus
have a hearing loss measurable with conventional pure tone
audiometry (Sanchez et al., 2005; Mazurek et al., 2010). There
are some patients, perhaps up to one in 10, who have tinnitus
in association with normal pure tone audiometry. However,
when more sophisticated investigations of cochlear function
such as high frequency audiometry (Vielsmeier et al., 2015) or
threshold equalizing in noise (TEN) testing (Weisz et al., 2006)
are undertaken, most if not all are found to have defects of
peripheral auditory function. It is often taken for granted that
one form of sensorineural hearing loss is much the same as
another, but is this really correct? Is tinnitus arising in someone
with noise induced hearing loss identical to the tinnitus in
someone whose sensorineural hearing loss is classified as age-
related hearing loss, ototoxic medication induced hearing loss
or post-head injury hearing loss? Without fully understanding
the pathophysiology of different forms of sensorineural hearing
loss and its relationship to tinnitus, researchers may well be
undertaking studies on heterogenous patient populations that
have different underlying mechanisms. This runs a significant
13https://en.oxforddictionaries.com/definition/tinnitus
risk that subtle treatment effects for specific groups may be
missed in the overall picture. Thus, it is possible that effective
treatments for some forms of tinnitus already exist, but this
effect has been overlooked because results for multiple subtypes
have been analyzed as a single group. An interesting example
of tinnitus research where test-subject heterogeneity may have
affected trial outcome is the story of gabapentin. As its name
suggests, gabapentin was initially thought to be a GABA receptor
agonist but is now recognized to have its effect by acting on
a subsection of voltage-gated calcium channels. It is marketed
as an anti-epileptic drug and is also used in the management
of certain types of pain. It has been explored in both human
and animal studies for possible use in tinnitus. The animal
study (Bauer and Brozoski, 2001) suggested that gabapentin was
effective at attenuating tinnitus secondary to noise exposure.
A subsequent single blind human study undertaken by the same
team (Bauer and Brozoski, 2006) suggested that gabapentin
was also effective in humans, particularly those whose tinnitus
etiology was associated with acoustic trauma. A double-blind trial
also reported that gabapentin was effective in treating tinnitus
secondary to acoustic trauma (Goljanian Tabrizi et al., 2017).
Several other studies, however, have not found gabapentin to
be effective (Piccirillo et al., 2007; Witsell et al., 2007; Dehkordi
et al., 2011). Only one of these studies divided their participants
into those who had experienced significant noise exposure and
those who had not (Dehkordi et al., 2011). A history of noise
exposure did not affect outcome in this study, though the
number of participants who reported sound exposure was low: 16
reported being in noisy environments and 6 reported exposure
to explosions. With this conflicting evidence, a large study with
robust etiological subtyping of participants would seem the
logical next step.
Clinical Trial Populations
A significant impediment to pharmaceutical industry
engagement in the development of new treatments for
tinnitus is the perception that, even when some evidence of
efficacy is observed in initial efficacy trials (Phase Ib or II),
efficacy seems to vanish once the treatment moves into Phase
III where the trial populations are more heterogeneous and
representative of the intended population once the drug is
approved. Participants with tinnitus who are enrolled into initial
Phase Ib or II trials often tend to be a discrete subset of the
general clinical population of tinnitus sufferers. For example,
early Phase Ib or II trial protocols may favor recent onset rather
than chronic tinnitus. This may be for mechanism-related
reasons: for example, a recent drug development programme
for the experimental drug, AM-101, which targets the N-methyl-
D-aspartate (NMDA) subtype of glutamate receptors in the
cochlea, was predicated on the hypothesis that noise-induced
tinnitus arises following damage within the cochlea and might
be prevented by early intervention within a few months of
the onset of tinnitus (Staecker et al., 2015). There is also a
perception that subjective tinnitus may be easier to treat early
on, before some of the psychological sequelae are established.
Thus, these early efficacy trials will try to give the drug the
best chance of exhibiting efficacy before moving into broader
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FIGURE 3 | The forms of negative reaction to real and phantom sounds.
populations of tinnitus sufferers. Similarly, early efficacy trials
often have an upper age limit of 65 years, which may be due
to limits on what may be known about the safety of a new
drug in the elderly at this stage of its clinical development,
however, since tinnitus increases in prevalence and severity with
age, elderly subjects will need to be included in larger Phase
III studies. Subjects with very high and catastrophized scores
on self-report questionnaires, and/or significant psychiatric
impact such as anxiety or depression are also frequently excluded
from early trials, despite this being a clinical scenario with very
high unmet need.
Another factor influencing early clinical trial design is the
evidence that there is a poor correlation between tinnitus
loudness and subjective suffering (Meikle et al., 1984).
Consequently, drug developers are often keen to dissociate the
two in early clinical trials. For example, in order to demonstrate
that a new drug targeting the pathophysiology of tinnitus within
the auditory system can reduce the tinnitus percept, it may be
important to focus on subjects with a consistent tinnitus, but who
have limited psychological sequelae associated with the tinnitus.
Robust efficacy is a must in early Phase II trials before
drug developers are likely to invest in the much larger Phase
III programmes, and thus it is likely that careful choice of
inclusion/exclusion criteria will continue. However, the choice
of these criteria needs to be better informed by a greater
understanding of the heterogeneity of tinnitus pathology,
clinical course, and demographic influences. Furthermore,
it may be important to conduct additional Phase II studies
in diverse populations (e.g., a specific study in the elderly
or in subjects with chronic tinnitus) before moving into
Phase III. Such expedient drug development strategies are
essential to render a clinical trial more straightforward
to run, but drug developers must not lose sight of the
unmet clinical need.
Clinical Trial Design
Following on from the expedient selection of tinnitus patients
for study, clinical trial design for novel therapies for tinnitus is
hampered by other important factors:
1. Lack of biomarkers, objective outcome measures and
treatment endpoints.
2. Uncertainly about the duration of treatment that may be
required to achieve an improvement.
3. A significant placebo effect that may mask treatment effect.
This situation is compounded by the small size of many
Phase II tinnitus clinical trials that have been conducted to date.
A further shortcoming is that trial design and endpoints have
varied considerably, making it difficult to pool or meta-analyze
the results across studies. A good example of this trial-design
problem is demonstrated by the use of repetitive transcranial
magnetic stimulation (rTMS) for tinnitus. Three editorial articles
(Ciminelli et al., 2016; Piccirillo, 2016; Mennemeier and George,
2017) make similar points, drawing from work in the field
of mental health: the use of rTMS for treatment resistant
depression was unclear for a long time because the evidence relied
on small trials using heterogenous methodologies. Eventually,
large, well-designed, multicentre trials were conducted which
demonstrated that rTMS does have a role in depression, for
specific patients using specific treatment protocols. All these
editorials recommended a similar approach is taken for tinnitus.
Tinnitus Measures and Biomarkers
As stated in the previous section, one recurring problem
with tinnitus research is that there is no objective way of
determining whether someone has tinnitus, no objective way
of determining the severity of that tinnitus and no objective
way of assessing whether treatments improve tinnitus. A recent
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systematic review examined the work to date on trying to find
suitable objective measures of tinnitus (Jackson et al., 2019). The
review identified 21 articles, studying objective tests that included
blood tests, electrophysiological measures, radiological measures
and balance tests. The review concluded that the quality of
evidence was generally poor and had failed to identify any reliable
or reproducible objective measures of tinnitus. A biomarker
can be defined as “a characteristic that can be objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes or pharmacological responses
to a therapeutic intervention” (Puntmann, 2009). Although this
may seem to be another way of describing an objective measure
of tinnitus, there are distinctions: a suitable biomarker for
drug effect or relevant neural process may not necessarily be a
measure of tinnitus or tinnitus pathology. Various candidates for
a tinnitus biomarker have been considered, including otoacoustic
emission testing, auditory brainstem responses (ABR), gap-
prepulse inhibition to acoustic startle, pupillometry, functional
imaging, magnetoencephalography, genetic markers, blood or
saliva components and markers of stress. Nothing has yet been
shown to offer the necessary specificity and sensitivity to be
used as a biomarker in tinnitus treatment. though some studies
have seemed tantalizingly close to discovering a biomarker: ABR
studies in tinnitus patients have shown increased latency and
reduced amplitude of ABR Wave I compared to measurements in
non-tinnitus control subjects (Milloy et al., 2017; Bramhall et al.,
2019). However, the findings have shown considerable variability
and lack of consistency between studies, suggesting that further
work in this area is needed. There have also been some interesting
preliminary findings in genetic studies of tinnitus patients.
A twins study (Maas et al., 2017) found evidence supporting a
degree of heritability in certain forms of tinnitus. A Swedish study
(Cederroth et al., 2019) attempted to disentangle the relative
contributions of genetic and environmental factors in medically
diagnosed tinnitus patients by exploring a large cohort of people
who had been adopted as children. This study suggested that
clinically significant tinnitus is associated with genetic factors,
with a heritability of 32% but that there is no association
between shared-environment factors. There are, however, other
studies that provide conflicting evidence regarding the genetic
contribution to developing tinnitus and this is another research
area deserving more detailed exploration.
One factor that hampers work into finding biomarkers is that
we do not yet have a large database of the non-audiological
phenotypes of tinnitus patients: collecting data such as the
biochemical, radiological and genetic characteristics of large
numbers of tinnitus patients has not been undertaken. Ideally
a biobank dedicated to tinnitus patients should be created
(Cederroth et al., 2017; Szczepek et al., 2019).
Whilst work using genetics to identify pharmacological targets
is in its infancy (Cook et al., 2014; Vona et al., 2017; Morgan et al.,
2018), it is reasonable to expect that further knowledge regarding
the genetic contribution to clinically significant tinnitus would be
of considerable value.
Without suitable objective markers or biomarkers, tinnitus
research in humans currently uses a range of audiometric and
self-report questionnaire measures to assess tinnitus severity and
treatment effect. Multiple such tools are available and there is
no consensus regarding optimum datasets for clinical research.
This makes subsequent comparison of trials and meta-analysis
of data problematic. A recent multinational working group has
tried to address this (Hall et al., 2015, 2019a; Fackrell et al., 2017)
and has proposed a basic portfolio of tinnitus “domains” that
should constitute a core outcome set for different types of tinnitus
research (Hall et al., 2018). Whilst this suggestion is laudable,
it remains to be seen if the tinnitus research community adopts
these recommendations and it does not provide the unequivocal
objective measure that the pharmaceutical industry desires.
A further limitation of the current tools for assessing tinnitus
impact is the reliability and repeatability of such measures: self-
report measures of tinnitus have an associated risk of variability,
as they supply a momentary snapshot whereas the experience
of tinnitus changes with time and context. One approach to
reducing that is to perform Ecological Momentary Assessment
(EMA) (Goldberg et al., 2017; Probst et al., 2017), a technique
also used in anxiety, stress, and pain trials (Yang et al., 2019).
Evidence regarding the utility of EMA in tinnitus trials is
emergent at present.
Tinnitus Pathophysiology
There are multiple proposed theories regarding the underlying
cause of tinnitus, but knowledge is sparse. Most consider that
tinnitus may be triggered in the peripheral or central auditory
systems or even from outside the classical auditory pathways.
Most theories also agree that the processes that cause tinnitus to
persist and create distress occur in the brain rather than the ear
(Baguley, 2006). Suggested mechanisms include reorganization
of the brain’s tonotopic map following deafferentation, increased
spontaneous neuronal firing within the auditory brainstem and
mid-brain, increased neuronal synchrony, failure of inhibitory
pathways, maladaptive auditory-somatosensory plasticity or
errors of predictive coding (Roberts et al., 2010; Schaette and
Kempter, 2012; Noreña and Farley, 2013; Sedley et al., 2016; Wu
et al., 2016; Gentil et al., 2019; Hullfish et al., 2019; Sedley, 2019).
Although we know much more about the pathophysiology of
tinnitus than we did a decade ago, much of our knowledge is
based on animal or computer modeling. Knowledge of what is
happening in humans is less clear and we do not yet have a way of
determining the pathological mechanism in an individual patient.
Animal Models of Tinnitus
Animal models have become widely used in tinnitus research,
particularly research regarding tinnitus pathogenesis and
research into pharmaceutical treatment of tinnitus (von der
Behrens, 2014; Eggermont and Roberts, 2015). Yet tinnitus
research literature has several instances where apparently
effective treatments in animal models have failed to work in
humans. Memantine is an antagonist of NMDA glutamate
receptors, used in some cases of dementia. Experimental
evidence suggested that it is effective in treating tinnitus arising
in rats after acoustic trauma (Zheng et al., 2012). A randomized,
double-blind study in humans, however, showed no significant
change in the primary outcome measure relative to placebo
(Figueiredo et al., 2008). Esketamine, the S(+) enantiomer of
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ketamine, is another NMDA glutamate receptor antagonist that
has been explored for use in acute tinnitus, administered as an
intratympanic injection. Despite promising animal data (Bing
et al., 2015) and initially optimistic human work a large-scale
human study, TACTT3-Trial14 failed to show efficacy. AUT00063
is an experimental drug that acts as a modulator of the Kv3.1
subtype of potassium channels. Animal research suggests that
the drug is very effective at reducing hyperactivity in the auditory
brainstem after noise exposure in rodents (Anderson et al., 2018;
Glait et al., 2018) and hence might be expected to be effective
against similarly generated tinnitus in humans. However, a
randomized controlled trial of AUT00063 in humans with
subjective tinnitus, QUIET-1, was halted because of lack of
efficacy (Hall et al., 2019b). This discrepancy between animal
models of tinnitus and clinical trials in humans has various
possible explanations: firstly, the pathophysiology of tinnitus in
humans may be different from that of laboratory animals (and
there remain significant questions about whether the animals
do experience tinnitus, and whether our methods for detecting
the symptom are reasonable). Secondly, where a drug has failed
to show efficacy in a human clinical trial after successful animal
studies, it is important to be sure that the drug adequately
engaged the pharmacological target in humans. The absence of
suitable translational biomarkers is a major hurdle to satisfying
this requirement. Thirdly, animal studies and human studies
measure different things: animal studies generally use either
behavioral tests or gap-prepulse inhibition of the acoustic startle
reflex (Galazyuk and Hébert, 2015) to define the presence or
absence of tinnitus whereas human studies use self-report and
quantify the tinnitus using questionnaires, rating scales or
psychoacoustic measures such as tinnitus loudness matching.
There is currently no translationally valid outcome measure that
can be used in both human and animal studies. Fourthly, some
animal studies use outcome measures that may not be detecting
tinnitus: the QUIET-1 study measured neural hyperactivity in the
dorsal cochlear nucleus of hamsters (Glait et al., 2018). Although
the authors argue persuasively that this neural hyperactivity
is indicative of tinnitus, other explanations are possible, and
the finding could represent hyperacusis rather than tinnitus.
Finally, animal studies are very often limited to acute dosing
with drugs, whereas clinical trials in humans explore efficacy
after multiple days or weeks of dosing. It is important to check
in animals that the drug effect does not reduce after chronic
dosing which might explain why no efficacy is seen in chronic
studies in patients.
It is important to observe that there have been studies
where animal and human tinnitus research concur, and it
would be wrong to dismiss animal research. Examples where
there is positive evidence to support the translational value
of animal research prior to human trials include bimodal
stimulation using either sound and electrical stimulation of the
cervical or trigeminal nerves (Marks et al., 2018) or sound and
electrical stimulation of the vagus nerve (Engineer et al., 2011;
Tyler et al., 2017).
14https://www.epgonline.org/global/news/keyzilen-fails-phase-iii-tactt3-trial-to-
treat-tinnitus---auris-medical-.html
Right Drug, Wrong Time?
It has long been suggested that tinnitus pathogenesis is a two-
stage process: an initial ignition which can be anywhere in the
auditory system including the cochlea, followed by a secondary
process of promotion which occurs in the central auditory
system and maintains the prominence of the percept (Baguley,
2006). Inherent in this hypothesis is the suggestion that there
may be different therapeutic targets, depending on the stage of
the tinnitus. Thus, cases of tinnitus ignited by damage to the
peripheral auditory system, may benefit from drugs aimed at the
cochlea, given at or soon after onset of the symptom, whereas
established tinnitus may need centrally acting drugs. What is not
clear, is the time frame for the change from peripheral to central
targets. Guitton et al. (2003) demonstrated in a rat model that
an NMDA antagonist, gacyclidine, administered to the cochlea
prevented salicylate induced tinnitus when given simultaneously.
As discussed above, Bing et al. (2015) produced data in an
animal model suggesting that an NMDA antagonist might benefit
noise induced tinnitus. In this trial, the drug was administered
2 days after noise trauma. Subsequent human trials such as
TACTT3 failed to demonstrate efficacy but included subjects who
had developed their tinnitus up to 3 months previously. This
topic regarding potential optimal therapeutic windows needs
further exploration.
There is also emerging evidence that the auditory system
reacts differently to both noxious stimuli and drugs depending
on the time of day. Meltser et al. (2014) demonstrated that
mice exposed to noise trauma all showed initial evidence of
hearing loss. However, those whose noise exposure was during
the daytime recovered within 2 weeks whereas those whose noise
exposure was at night developed permanent hearing loss. By
experimentally activating tropomyosin receptor kinase type B
(TrkB) using a selective agonist, 7,8-dihydroxyflavone (DHF), the
mice could be protected against nocturnally induced hearing loss;
DHF made no difference to the temporary hearing loss produced
by diurnal noise exposure. The relevance of these findings to
humans, to tinnitus and to human drug administration remains
to be established but EMA measurements have demonstrated
that tinnitus loudness varies throughout the day (Probst et al.,
2017), suggesting that tinnitus may also be under the influence of
circadian factors.
Setting Treatment Goals
Partly because of a lack of suitable outcome measures, defining
what constitutes a cure is problematic. Various studies have
looked at the existing tinnitus questionnaire tools and estimated
a value for minimum meaningful change (Zeman et al.,
2011; Adamchic et al., 2012; Fackrell et al., 2016) but this
represents the smallest change above the measurement error
and clinically this is improvement rather than cure. Similarly,
use of tinnitus loudness estimates is flawed because of poor
sensitivity and large measurement error (Hall et al., 2017).
It is likely that tinnitus patients would suggest that the
answer to defining a cure is simple: complete eradication
of the tinnitus percept. However, several studies (Heller and
Bergman, 1953; Del Bo et al., 2008) have shown that people
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FIGURE 4 | The British Tinnitus Association Tinnitus Cure Map. A representation of tinnitus research areas. An interactive version accessed via the internet is being
developed, demonstrating knowledge gaps but also demonstrating areas where we already know the answer and blind alleys that do not need further exploration.
The interactive version will connect to other internet resources via hyperlinks. For purposes of clarity, this version of the Cure Map has been limited to three levels.
A more comprehensive version with four levels is included in Supplementary Material.
with normal ears, normal hearing and no tinnitus become
aware of phantom auditory perceptions when they are placed
in soundproof environments. It may therefore be unrealistic
to set total eradication of tinnitus percept as the primary
goal and more work is needed to ascertain what healthcare
providers, purchasers and patients will accept as a clinically
meaningful improvement in order to guide clinical trial design.
Although sounding less positive, it may be preferable to use
different terminology and set the goal as remission from
tinnitus rather than the more semantically confusing concept
of “cure.”
Healthcare Organization
Other potential hurdles to attracting pharmaceutical research
interest are the lack of a clear route to market with no established
regulatory pathway and the lack of a precedent for pricing
and reimbursement of a tinnitus drug. Another issue that is
particularly relevant to the American healthcare market is the
lack of a suitable healthcare structure for tinnitus patients –
most patients in the United States currently see audiologists, who
cannot prescribe medication. Clearly all of this might change
if a promising drug therapy were to make its way through
clinical trials.
ROADMAP TO A CURE
Development of Tinnitus Cure Map
The preceding text demonstrates the challenges of tinnitus
research. We need more focus on definitions, subtyping and
outcome measures; we need research that uses common
methodologies, making comparison and meta-analysis easier; we
need to ensure that researchers are focussed on what funders and
patients want. To try and clarify this complex subject, the British
Tinnitus Association (BTA)15 has developed a Tinnitus Cure Map.
This is an attempt to try and summarize the current tinnitus
research, demonstrating knowledge gaps but also demonstrating
areas where we already know the answer, blind alleys that do not
need further exploration. The aim is also to highlight research
opportunities and act as an up to date repository of evidence-
based tinnitus knowledge.
The map was developed within the BTA and involved
consultation with relevant stakeholder groups, including
members of tinnitus patient support groups, BTA members, BTA
Professional Advisers Committee members and British Society
15https://www.tinnitus.org.uk/
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of Audiology Tinnitus and Hyperacusis Special Interest Group16.
Criteria were that the map should be free to access, intuitive and
easy to use, adaptable and expandable.
A paper copy of the map has been produced using four
heading levels: Steps Toward a Cure, General Research Area,
Specific research Area and Individual Projects. A copy of the map
limited to three levels for clarity is shown (Figure 4). A version
that uses four levels is included in Supplementary Material.
An electronic version is under development. This has no
theoretical limit to the number of levels and this version utilizes
pop-ups to display detailed content and hyperlinks to external
content. The external content is the highest level of evidence
available on that topic, using the Oxford Centre for Evidence-
based Medicine17 criteria.
The Tinnitus Cure Map as a Lobbying
Tool
In addition to providing a comprehensive repository of the
current evidence base regarding tinnitus, we hope that the map
can be used by charities, other patient groups and individual
tinnitus patients to demonstrate to politicians, research funders,
the pharmaceutical industry and healthcare organizations the
size of the tinnitus problem and the need for a much enhanced
research footprint.
CONCLUSION
Whilst an encouraging upturn in the volume of tinnitus research
being performed is evident, it is also apparent that a step
change will be needed to deliver progress toward truly effective
treatments. Several building blocks for that need putting in place,
including biomarkers, robust outcome measures, and meaningful
subtyping of clinical phenotypes. Such work will need to be
16https://www.thebsa.org.uk/bsa-groups/tinnitus-hyperacusis-special-interest-
group/
17https://www.cebm.net/2016/05/ocebm-levels-of-evidence/
interdisciplinary and international and will need to engage
researchers and clinicians along the whole of the translational
research pathway. The role of industry in this endeavor is
fundamental, utilizing experience in clinical trial design, and
attracting resources for large scale trials that intentionally address
the clinical need, incorporating the views of patients/families as
well as clinicians and researchers. The opportunities for societal
financial benefit and the alleviation of tinnitus related burden and
distress are substantial.
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